Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6 @RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA

• Updates on New Treatments for SpA: Drs. Antoni Chan and Laura Coates | RheumNow

Supporting date for Ixekizumab in PsA with symptoms of axial involvement. 🔹Improvement in QoL (SF-36), ASDAS, BASDAI50 🔹Maintained at 52 weeks 🔹Stricter criteria (younger, ⬆️CRP) showed similar results https://t.co/QSJLQTxLcW #ACR21 Abst#3147 @RheumNow

• Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Sympto…

Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg

Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21 https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG

• https://bit.ly/3wt5M1V

Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed

• Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthrit…

Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

• Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Am…

SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX

• Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthr…